Condition
Aspartylglucosamidase (AGA) Deficiency
Total Trials
3
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
Treatment Research
1 treatments under study, led by Scaav9aga
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.6% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
1Total
Phase 1/2 (1)
Trial Status
Recruiting1
Enrolling By Invitation1
Terminated1
Clinical Trials (3)
Research Network
Common Treatments
- Scaav9aga1
Active Sponsors
- Rare Trait Hope2
- Neurogene Inc.1
Top Investigators
Neurogene Inc.
Related Conditions
- Aspartylglucosaminuria3
- Lysosomal Storage Diseases1